Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on March 11, 2009, to report a significant corporate event. The Company is a biopharmaceutical firm incorporated in Florida with principal executive offices in Carmiel, Israel.
Key Financial Metrics
This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific grant award.
Material Changes
On March 11, 2009, the Office of the Chief Scientist (OCS) of Israel's Ministry of Industry, Trade and Labor awarded the Company a grant of over $6 million for calendar year 2009. This funding is designated to promote the advancement of the Company's clinical and preclinical drug development programs.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the announcement of the grant. The primary outlook implication is the availability of non-dilutive funding for R&D activities in 2009.
Investor Verification Checklist
- Verify the specific terms and conditions of the $6 million grant from the OCS.
- Confirm the allocation of funds between clinical and preclinical programs.
- Review the attached press release (Exhibit 99.1) for detailed milestones associated with the grant.